Trial · NCT01333592

Long-term Study of KAD-1229 in Type 2 Diabetes Patients

NCT01333592, Phase 3, Completed, Kissei Pharmaceutical Co., Ltd.; results first posted 2014-11-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Long-term Study of KAD-1229 in Type 2 Diabetes Patients. Trials, record NCT01333592. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01333592

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Long-term Study of KAD-1229 in Type 2 Diabetes Patients
NCT number: NCT01333592
Status: Completed
Phases: Phase 3
Enrollment: 136 participants, actual
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: KAD-1229
First posted: 2011-04-12
Last updated: 2014-12-15
Results first posted: 2014-11-24

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Incidences of Adverse Events	52 weeks
Secondary	Change From Baseline in HbA1c at 52 Weeks	at week 0 and week 52

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
SECONDARY	Change From Baseline in HbA1c at 52 Weeks	at week 0 and week 52		percentage of HbA1c	MEAN
PRIMARY	Incidences of Adverse Events	52 weeks		Participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline in HbA1c at 52 Weeks	KAD-1229 / DPP-4 Inhibitors	-0.45	Standard Deviation 0.69	percentage of HbA1c
Change From Baseline in HbA1c at 52 Weeks	KAD-1229 / Biguanides	-0.28	Standard Deviation 0.63	percentage of HbA1c
Incidences of Adverse Events	KAD-1229 / DPP-4 Inhibitors	48		Participants
Incidences of Adverse Events	KAD-1229 / Biguanides	57		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	KAD-1229 / DPP-4 Inhibitors	67
Overall Study	STARTED	KAD-1229 / Biguanides	69
Overall Study	COMPLETED	KAD-1229 / DPP-4 Inhibitors	58
Overall Study	COMPLETED	KAD-1229 / Biguanides	52
Overall Study	NOT COMPLETED	KAD-1229 / DPP-4 Inhibitors	9
Overall Study	NOT COMPLETED	KAD-1229 / Biguanides	17

Source ClinicalTrials.gov

Adverse events40

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Bronchitis	Infections and infestations	KAD-1229 / DPP-4 Inhibitors	2	67
other	Bronchitis	Infections and infestations	KAD-1229 / Biguanides	8	69
other	Nasopharyngitis	Infections and infestations	KAD-1229 / DPP-4 Inhibitors	17	67
other	Nasopharyngitis	Infections and infestations	KAD-1229 / Biguanides	30	69
other	Pharyngitis	Infections and infestations	KAD-1229 / DPP-4 Inhibitors	6	67
other	Pharyngitis	Infections and infestations	KAD-1229 / Biguanides	2	69
other	Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	KAD-1229 / DPP-4 Inhibitors	5	67
other	Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	KAD-1229 / Biguanides	5	69
other	Dental caries	Gastrointestinal disorders	KAD-1229 / DPP-4 Inhibitors	0	67
other	Dental caries	Gastrointestinal disorders	KAD-1229 / Biguanides	4	69

1 to 10 of 40Source ClinicalTrials.gov

See all 40 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	KAD-1229 / DPP-4 Inhibitors
Total, all-cause mortality	KAD-1229 / Biguanides
Total, other adverse events	KAD-1229 / DPP-4 Inhibitors	34	67
Total, other adverse events	KAD-1229 / Biguanides	47	69
Total, serious adverse events	KAD-1229 / DPP-4 Inhibitors	1	67
Total, serious adverse events	KAD-1229 / Biguanides	5	69

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
KAD-1229 / DPP-4 Inhibitors vs KAD-1229 / Biguanides: Incidences of Adverse Events	Trial comparisons
KAD-1229 / DPP-4 Inhibitors vs KAD-1229 / Biguanides: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01333592

GET https://conductscience.org/api/trials/v1/NCT01333592/events?page=2

API reference For AI assistants